Just got my two checks yesterdays mail.

FYI, When I looked into this at day one, I read the returned money would be put back into my ira accounts which had sold them for a loss, but that is how I bought the shares, through roth ira and standard ira accounts.

Same here...

Hmmn. I sent in a claim for a standard ira account with td and a second claim for a roth ira, also with td, both in the same envelope. I received one postcard for each, with a different claim id. I also found them on the list posted. Thanks to the list poster, by the way.

HO HO.. I remember that. I sold 9 million shares a week before when it jumped to .0004... thats what i do.... lol..

hey Mike,
Thanks for your dd and and all info on this company. I will invest not on your say so but because of all the associated info i have gleaned. but thanks !

Wow ! old news here for most , but I like it !


BIXT
-1.71%
Wed, November 16, 2022 at 7:00 AM
In this article:




Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)

Complete elimination of viral load in 88% of patients at day 3 vs 0% in placebo (p=.001)

Treated population experienced no viral rebounds within the 14-day observation period

BOSTON, Nov. 16, 2022 /PRNewswire/ -- BIOXYTRAN, INC. (OTCQB: BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value = .001). Our analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE's) in the patient population or viral rebounds by day 14 in the patient population. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.

The full text of the preprint is located at the following link.
https://www.medrxiv.org/content/10.1101/2022.11.09.22282151v1

Nuclear Magnetic Resonance ("NMR") testing was used to elucidate the Mechanism of Action of the specific Galectin Antagonist. Tests concluded that ProLectin-M ("PL-M") binds relatively strongly to galectin-3 with micromolar affinity down to 2µM. While the Galectin Antagonist does indeed bind to the S1 Spike Protein, the study showed that it could bind in 2 different orientations with galectin-3. The NMR binding data indicate that 5 molecules of galectin-3 are required to saturate one spike protein. These findings on the mechanism of action supported the decisions on dosing, duration, and ingestion. The results showed PL-M's inhibition of galectin-3 and the blockade of the N-Terminal Domain of the S-1 subunit.

"Our sights were set on a statistically significant reduction of viral load by day 7 because we expected that there would be real-world issues that we would be unable to account for in our theories about efficacy. We can say that these trial results exceeded our expectations by orders of magnitude, but the proof of that statement lies in our trial design which should have been hourly instead of daily so that we would have had a more detailed picture of how rapidly the viral load was dropping" said Dr. Alben Sigamani, Bioxytran Medical Advisory Board .

https://www.benzinga.com/pressreleases/22/10/g29392723/bioxytran-scientific-advisor-releases-new-book-on-brain-metabolism

Bioxytran Scientific Advisor Releases New Book on Brain Metabolism

here is some judgement data from 2019 or so.


https://www.sec.gov/litigation/complaints/2019/judgement-pr2019-255.pdf



1. All three Defendants are enjoined from participating in an offering of penny stock,
defined as “any equity security that has a price of less than five dollars, except as provided in 17
C.F.R. § 240.3a51-1,” including engaging in activities with a broker, dealer, or issuer for
purposes of issuing, trading, or inducing or attempting to induce the purchase or sale of any
penny stock. This injunction as against Mr. Friedland and Global shall be in place for a period of
10 years from the date of this Judgment; the injunction as against Intiva shall be permanent.

My letter states:


"Claim is considered eligible under the terms and conditions of the approved Distribution Plan "

For whatever that is worth..lol !

Solutions

September 12, 2022 09:00 AM Eastern Daylight Time
ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International announced today data and patent filing on a new approach to treating chronic obstructive pulmonary disease (COPD).

“Our Company is committed to curing COPD. To develop a real cure, we need to create a protocol that utilizes both exogenous stem cell administration, such as JadiCells, as well as properly stimulating the patient’s endogenous regenerative mechanisms using approaches such as the one disclosed today”


The Company demonstrated that administration of a combination of the FDA approved drug G-CSF, together with a proprietary anti-oxidant/NF-kappa B inhibiting formulation resulted in suppression of COPD in the elastase animal model. Furthermore, the Company demonstrated synergy between the new approach and JadiCell administration.

“Our Company is committed to curing COPD. To develop a real cure, we need to create a protocol that utilizes both exogenous stem cell administration, such as JadiCells, as well as properly stimulating the patient’s endogenous regenerative mechanisms using approaches such as the one disclosed today,” said Dr. James Veltmeyer, Chief Medical Officer of the Company.

Therapeutic Solutions International currently has an ongoing Phase III clinical trial for COVID-19 induced Acute Respiratory Distress Syndrome and has been granted an IND number by the FDA for treatment of COPD.

Yessss, fantastic ! and i reallllly mean that. but then, i am on medication.

Been away for a while, but found this and was wondering what ya all think about this . Pro, and or, con .


"Snakes & Lattes FQ3 revenue of $1.5M
May 16, 2022 9:51 AM ETAmfil Technologies Inc. (FUNN)By: Mary Christine Joy, SA News Editor
Snakes & Lattes Inc. press release (OTCPK:FUNN): FQ3 Revenue of $1.5M.
Cash on hand at the end of the quarter was $53,427.
For FQ4, revenue should be north of $2M.
The company said its newest locations in Glendale, CA, and Provo, UT, will also be part of the revenue on future statements."

Is this TSOI 's ?



"Study NCT04355728
Submitted Date: December 1, 2021 (v10)
Open or close this module Study Identification
Unique Protocol ID: 20200671
Brief Title: Use of UC-MSCs for COVID-19 Patients
Official Title: Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)
Secondary IDs: 20200370 [Secondary Protocol ID]
Open or close this module Study Status
Record Verification: December 2021
Overall Status: Completed
Study Start: April 25, 2020
Primary Completion: October 31, 2020 [Actual]
Study Completion: October 31, 2020 [Actual]
First Submitted: April 13, 2020
First Submitted that
Met QC Criteria: April 17, 2020
First Posted: April 21, 2020 [Actual]
Results First Submitted: October 15, 2021
Results First Submitted that
Met QC Criteria: December 1, 2021
Results First Posted: December 6, 2021 [Actual]
Last Update Submitted that
Met QC Criteria: December 1, 2021
Last Update Posted: December 6, 2021 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Camillo Ricordi
Responsible Party: Sponsor-Investigator
Investigator: Camillo Ricordi
Official Title: Professor of Surgery and Chief, Division of Cellular Transplantation
Affiliation: University of Miami
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)."

This is likely old news to most here, but I offer this tidbit.

"Available

July 18, 2022 09:00 AM Eastern Daylight Time
ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International announced today granting of Emergency IND # 28685 and a “May Proceed Notification” from the Food and Drug Administration (FDA) for the treatment of advanced COVID-19 ARDS outside of the currently ongoing Double Blind Placebo Controlled Phase III clinical trial for the same indication. The Company previously announced treatment of 15 "no option patients” under both “eIND” and “Right to Try” Law1.

“We are blessed to have very positive relations with the FDA which has allowed for rapid movement through the various regulatory hurdles involved in development and commercialization of stem cell therapies.”

Tweet this
“Based on my clinical experience with the JadiCells, their therapeutic effects are unparalleled in comparison to any other stem cell therapy,” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. “With the increase in COVID-19 cases, as well as the anticipated deluge of COVID-19 ‘long hauler’ patients, it is imperative that we have mechanisms to provide these cells to patients who desperately need them, even if it is outside of the clinical trial. Our number one mission as a Company is to accelerate development of these cells as rapidly as possible and to save people’s lives.”

Previously the Company has demonstrated superior activity of JadiCells to other stem cells, as well as identifying mechanisms of action2,3. The JadiCell is currently in Phase III for COVID-19 ARDS4, has been granted IND numbers for COPD5, and Chronic Traumatic Encephalopathy6, and is in late preclinical development for Idiopathic Pulmonary Fibrosis7."

Hello Clean, I sent my stuff in early April and received my card about two weeks ago..

That one was for my roth ira account. Today I got a postcard for my standard ira account.,.. told me if any more info was needed, I would be contacted later.

Hi BigBadWolf ! Thanks for the video/music ! Made me smile, as since my verry poor investments with many of these penny stocks - the song pretty much is about me .... LOL

GLTA and go Therapeutic Solutions !

Joe, I sent my stuff in around early April and just got my receipt postcard yesterday.

Hello Cents, glad to read you out and about.. Take care and have a great healthy weekend..

I woke up again and am happy ! lol GLTA and TSIO !

ForeignCitizen

Thursday, July 14, 2022 9:47:56 AM

Re: None

Post#
61611
of 61629
No Reverse Split.


why?

well, there should be a pot pill.... beer just adds on weight... soory I digress with too much ipa and bored... GLTA

Good day to you and all here.. !

I have had stock in tsio since covid crap started and really want it to go well.....but the trial you post is a negative to me rather than a positive.. in small print it reads status unknown for two years.... What is that all about ?

Drinkin ipa , if if this makes no sense.. excuse me.. lol

in 20 years ..this has never worked for me... bye all

Wow ! Kinda quiet here lately.. Everyone feeling ok ? been here for several years and with invest and just kinda eaves drop from time to time... GLTA

Yes , the magic is in the eyes of the beholder !

Tks swamp boy for the info. I sent mine in about 60 days ago and have not heard from them. It would suck to lose out any benefit because of a minor technicality.

...yes.....lol

Just for fun .



PeterBPeterB2 days ago
I agree this is going to be big! I have 109,000 shares. Keep in mind over 2 Billion shares exist so to get to the point where it can safely list on NASDAQ this needs to be a company worth 3 Billion dollars or more. Will get there, but might take some time yet.

Reply

hmmn, sounds good, as I lost over 30000 back then... tks for info. mike

Thankyou both, that is very encouraging and gives me more info to learn about...

I thankyou for the info and after reading, have another question for you and anyone here, since I have read you have some experience in this area.

My girlfriend has 24 hour migraine, but with doctor's meds and 13 shots of Botox, she is mostly able to get off the couch. Anyones experience with the best product from tsoi for this would be appreciated and should be helpful to others.
Thank you

P.S. I also have the same governor, holding me to three ipa a day.. lol

I have stock in this company and have bought the product... if they suggest 3 a day ... isn't three a day what I should be taking, or does someone here know more than the company ? I want to know for my self what i should be taking ... ?

why ?

Tks for your honesty..

is he buying the shares and making the stock price go up ?

soo, why is this going back up again ?

I feel your pain, my history exactly, cept this time I have not bothered to sell, because my stock worth is sooo low...

Hello 'uber darthium' ... You just lost any credibility you had with this statement....



uber darthium Tuesday, 12/28/21 07:47:28 PM
Re: sosjtb post# 27992
Post #
27993
of 28005
Wired streetlights don’t have to communicate with a vehicle approaching the light at 35-55 mph (51-80 feet per second), limited to 100mW, and having to overcome a 25 dB polarization mismatch.

Lights are easy